RxDoctor Payments Data

Andrew Coccia

Urology · Voorhees, NJNPI 1649804576

Payments from drug & device makers

$1,775in general payments, 2019–2025

Across 51 payments — averaging $34.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$489
  • Boston Scientific$205
  • Clarus Therapeutics Inc.$155
  • Teleflex LLC$153
  • Calyxo, Inc.$146
  • Sumitomo Pharma America, Inc.$130
  • plus $498 from 12 others

What the payments were for

  • Food & beverage$1,775100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,775 in reported general payments places this provider in the 40th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$40,294
Medicare patients
309
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron59$33,666
GemtesaVibegron17$7,993
Tamsulosin Hcl672$6,565
Testosterone16$2,024
Testosterone Cypionate36$1,369
Finasteride101$1,157
Oxybutynin Chloride ErOxybutynin Chloride48$1,135
Methenamine Hippurate13$698
Oxybutynin Chloride28$682
Dutasteride12$434
Alfuzosin Hcl ErAlfuzosin Hcl34$305
Tadalafil16$199
Cephalexin43$175
Doxycycline Hyclate20$122
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$106$33,66659 claims
Sumitomo Pharma America, Inc.Gemtesa$130$7,99317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 401 urology providers in New Jersey.

Other urology in Voorhees

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →